Section Arrow
TLSI.NASDAQ
- TriSalus Life Sciences
Quotes are at least 15-min delayed:2024/05/28 14:11 EDT
Last
 7.85
+0.29 (+3.84%)
Day High 
7.9 
Prev. Close
7.56 
1-M High
10.24 
Volume 
70.73K 
Bid
7.85
Ask
7.88
Day Low
7.57 
Open
7.78 
1-M Low
6.8 
Market Cap 
205.32M 
Currency USD 
P/E -- 
%Yield
10-SMA 9.62 
20-SMA 9.59 
50-SMA 9.65 
52-W High 16.24 
52-W Low 3.32 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.54/-1.21
Enterprise Value
206.57M
Balance Sheet
Book Value Per Share
-1.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
18.51M
Operating Revenue Per Share
0.48
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CATXPerspective Therapeutics1.525+0.025+1.67%-- 
NUWENuwellis0.3079+0.058651+23.53%-- 
MDTMedtronic plc82.21-0.08-0.10%26.12PE
PACBPacific Biosciences of California1.86-0.01-0.53%-- 
ZOMZomedica Corp0.1727-0.0033-1.88%-- 
Quotes are at least 15-min delayed:2024/05/28 14:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.